How we deliver innovations that can change the lives of billions

Every two seconds, someone between the ages of 30 and 70 dies prematurely from a chronic disease such as cancer, heart disease, or a stroke. By far the largest burden falls on low- and middle-income countries, which account for 86% of these premature deaths [1]. All over the world, ageing populations are contributing to the rise of such diseases, resulting in higher demand for accessible and efficient healthcare. This adds to the challenges of healthcare providers already grappling with a shortfall of 11 million workers in the healthcare sector by 2030 [2], and budgetary strains.

Institutions and care systems need reliable partners with innovative ideas and technologies, an established research and development infrastructure, and the financial means to deliver on commitments.

Jochen Schmitz, Chief Financial Officer and Managing Board Member at Siemens Healthineers, loves numbers, of course. But mostly, he says, he appreciates analytical thinking and the team work behind every achievement. 

Why do you think Siemens Healthineers is in a position to address these huge global health challenges? 

“With our unique strengths, we are very well positioned to tackle the most threatening diseases while offering innovative ideas and technologies to our partners to battle staff shortages and the rising demand for healthcare. Those strengths include our global and unmatched portfolio that we bring to bear on local problems in a very real way, the healthcare AI that lifts our technology to new levels, and our large and growing presence in emerging markets.

We have a new strategic ambition that we call “Elevating health globally,” and we are serious about increasing our impact.

We will achieve that by expanding our clinical relevance in non-communicable diseases and precision therapy with our deep clinical expertise and state-of-the-art technologies. We will focus on cancer, stroke, neurogenerative, and cardiovascular diseases – four groups of non-communicable diseases with immense combined consequences for millions of lives. To support this goal, we are aligning our financial reporting structure with this strategic direction. Our business will be structured along three segments starting in our new fiscal year 2026. Alongside Imaging and Diagnostics, we have created a new segment called “Precision Therapy” that unites our treatment-focused businesses: Varian, Advanced Therapies and Ultrasound.”

How does the company drive innovation forward?

“Research and development are what keep us innovative, and innovation is the engine of our growth. That’s why we commit to keep investing 8-9% of our revenue in research and development every year – and as our revenue grows, so do those investments and so does our impact on global healthcare.

One of our superpowers is the way we combine digital twinning, precision therapy, and healthcare AI. And our strength lies in the close connection between research, clinical practice, and customer proximity. These are what will shape the progress of healthcare in the next years – and they offer continuous value-creation potential for us as a company and for society.

Did you know that only 1 percent of global healthcare costs is linked to our products and services – yet the impact is extraordinary? We are committed to amplifying this impact even further and creating greater value for healthcare providers worldwide. For our company, this translates into reliable revenue, compound growth in earnings, and ultimately a great investment case. We are a market leader in most of our segments, and it makes a difference if you manufacture, for example 3,000 MRIs instead of 500. This gives us several advantages, one of which is economies of scale that boost our gross margins, which is essential because it reflects how efficiently we turn revenue into profit, providing the resources to invest in growth and innovation. On the other hand, this sustained investment in R&D secures innovator margins and drives market shares. Our unwavering commitment to R&D investment has enabled breakthroughs like photon-counting CT. Looking ahead, it is exactly this that will elevate healthcare AI to the next level.

For the fiscal years 2027-2030, we are targeting 6-9% revenue growth for Imaging and Precision Therapy combined, while Diagnostics is expected to improve towards mid-single-digit growth. For the group, this translates to a 5-7% growth rate. In adjusted earnings per share, we target double-digit percentage growth annually.”

How do this financial strength and new strategy translate into real benefits for healthcare providers and society?

“Our customers need efficiency, clinical excellence and the ability to actually reach more and more patients. As a market leader, we are well positioned to help them overcome the biggest challenges – through so-called Value Partnerships, Value Programs and a large and growing presence in emerging markets.

Customers may face limited access to global best practices. With our Value Partnerships, we commit to long-term collaborations that are mutually beneficial – they learn from our global experience, while we learn from their lived experience. Our new Value Programs address a lack of standardization or resources; with our strong footprint in imaging around the world, we can help customers lift the impact of what they do in addressing specific non-communicable diseases.  And, by expanding our impact in emerging markets, we help address the burden of these diseases through tailored and cost-effective solutions – especially in low- and middle-income countries. It’s a sad fact that more than half of the world’s population still lacks access to essential health services.”

Are you a journalist and want to talk to Jochen to dive deeper into that? Reach out to press officer Ulrich Künzel, ulrich.kuenzel@siemens-healthineers.com.

At our Capital Markets Day in London this week, we shared the cornerstones of our strong performance across our businesses and showcased our new strategic ambition Elevating Health Globally – for greater impact on patient care, using artificial intelligence as a key lever to help healthcare providers work more efficiently and offer more personalized care. By bringing together investors, analysts, and the top management of Siemens Healthineers, such events provide an opportunity to share progress, clarify priorities, and demonstrate accountability.

This dialogue strengthens confidence in the company’s direction and fosters the trust that is essential for sustainable growth.

Find the press release, presentations and the recordings from the Capital Markets Day here: Capital Markets Day 2025

From November 30 to December 4, the Radiological Society of North America (RSNA) – the world’s largest professional society for radiology – will host its annual meeting with the theme: “Imaging the Individual.”

This year’s focus is all about exploring new frontiers, pushing boundaries, and exploring the future of precision medicine and inclusivity. Siemens Healthineers is proud to present innovative solutions designed to support patients and physicians wherever they are. Stay tuned for updates – we can’t wait to share what’s next!  

Learn more: RSNA 2025 - Annual Radiology Conference - Siemens Healthineers

Before we say goodbye, let’s share some latest news:  

• Together with 74,000 colleagues in more than 70 countries, we are honored to represent one of the World’s Best Workplaces in 2025.
• Siemens Healthineers successfully closes 2025 fiscal year in challenging environment 

Sources

[1] World Health Organization (2022): Invisible numbers – The true extent of noncommunicable diseases and what to do about them 

[2] World Health Organization (2025): Health workforce